etamivan

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 447989190

| IUPAC_name = N,N-Diethyl-4-hydroxy-3-methoxybenzamide

| image = Ethamivan.svg

| width = 200

| tradename = Analepticon

| routes_of_administration =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 304-84-7

| ATC_prefix = R07

| ATC_suffix = AB04

| PubChem = 9363

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB08989

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 8996

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = M44O63YPV9

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D04080

| C=12 | H=17 | N=1 | O=3

| smiles = CCN(CC)C(=O)c1ccc(O)c(OC)c1

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = BQJODPIMMWWMFC-UHFFFAOYSA-N

}}

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug{{cite journal | vauthors = Hirsh K, Wang SC | title = Respiratory stimulant effects of ethamivan and picrotoxin | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 193 | issue = 2 | pages = 657–63 | date = May 1975 | pmid = 1173598 }} related to nikethamide. It was mainly used in the treatment of barbiturate overdose{{cite journal | vauthors = Wheeldon PJ, Perry AW | title = The use of ethamivan in the treatment of barbiturate poisoning | journal = Canadian Medical Association Journal | volume = 89 | pages = 20–2 | date = July 1963 | issue = 1 | pmid = 14000228 | pmc = 1921664 }} and chronic obstructive pulmonary disease,{{cite journal | vauthors = Sproule BJ, Jans RL, Breitkreutz H, Mahon W | title = Effects of ethamivan in patients with chronic respiratory disease | journal = Canadian Medical Association Journal | volume = 91 | pages = 1203–8 | date = December 1964 | issue = 23 | pmid = 14226094 | pmc = 1928498 }} but has now largely fallen into disuse.

Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.{{cite book |page=N-61 |title=AMA Drug Evaluations |edition=3rd |date=1977 |publisher=Pub. Sciences Group |location=Littleton, Mass. |author=American Medical Association Dept of Drugs |isbn=978-0-88416-175-2 |oclc=1024170745}}